+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "CAR T Cell"

Cancer Immunotherapy - Global Strategic Business Report - Product Thumbnail Image

Cancer Immunotherapy - Global Strategic Business Report

  • Report
  • December 2025
  • 291 Pages
  • Global
From
Antineoplastic Agents - Global Strategic Business Report - Product Thumbnail Image

Antineoplastic Agents - Global Strategic Business Report

  • Report
  • December 2025
  • 183 Pages
  • Global
From
CAR T-cell Therapy - Global Strategic Business Report - Product Thumbnail Image

CAR T-cell Therapy - Global Strategic Business Report

  • Report
  • December 2025
  • 179 Pages
  • Global
From
Immunotherapy Drugs - Global Strategic Business Report - Product Thumbnail Image

Immunotherapy Drugs - Global Strategic Business Report

  • Report
  • December 2025
  • 193 Pages
  • Global
From
Cancer Therapies - Global Strategic Business Report - Product Thumbnail Image

Cancer Therapies - Global Strategic Business Report

  • Report
  • December 2025
  • 590 Pages
  • Global
From
Cancer Gene Therapy Market Report 2025 - Product Thumbnail Image

Cancer Gene Therapy Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
From
From
From
From
CAR T-cell Therapy Market 2025-2029 - Product Thumbnail Image

CAR T-cell Therapy Market 2025-2029

  • Report
  • January 2025
  • 199 Pages
  • Global
From
Cancer Gene Therapy Market - Forecasts from 2025 to 2030 - Product Thumbnail Image

Cancer Gene Therapy Market - Forecasts from 2025 to 2030

  • Report
  • August 2025
  • 152 Pages
  • Global
From
From
From
From
From
From
From
From
Loading Indicator

CAR T Cell therapy is a type of immunotherapy used to treat certain types of cancer. It is a type of gene therapy that uses a patient's own immune cells to recognize and attack cancer cells. The patient's T cells are collected and modified to express a chimeric antigen receptor (CAR) that binds to a specific antigen on the surface of the cancer cells. The modified T cells are then infused back into the patient, where they can recognize and attack the cancer cells. CAR T Cell therapy has been approved for the treatment of certain types of blood cancers, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). It is also being studied for the treatment of other types of cancer, including solid tumors. CAR T Cell therapy is a rapidly growing field, with many companies developing and marketing products. Some of the major players in the market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Cellectis. Show Less Read more